Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019. ATOR-1017 is a monoclonal antibody in development for the treatment of metastasizing cancer. It activates the costimulatory receptor 4-1BB and its immunostimulatory function is dependent on cross-linking to Fc-gamma receptors on immune cells. The new data show that ATOR-1017, in an experimental model for colon cancer (MC38),